6-chloro-2-(trifluoromethyl)-1,2-dihydro[1,8]naphthyridine-3-carboxylic acid | 215123-79-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-chloro-2-(trifluoromethyl)-1,2-dihydro[1,8]naphthyridine-3-carboxylic acid
• 英文别名: 6-Chloro-2-(trifluoromethyl)-1,2-dihydro[1,8]napthyridine-3-carboxylic acid；6-chloro-2-(trifluoromethyl)-1,2-dihydro-1,8-naphthyridine-3-carboxylic acid
• CAS: 215123-79-8
• 化学式: C₁₀H₆ClF₃N₂O₂
• 分子量: 278.618
• InChiKey: GAQLCAMYZGDGAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  Ethyl 6-chloro-2-(triflouromethyl)-1,2-dihydro[1,8]napthyridine-3-carboxylate 、 sodium hydroxide 、 甲醇 、 水 在 四氢呋喃 、 甲醇 、 乙醚 、 solid 、 Acetone ethanol 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以providing the title compound as a yellow solid (276 mg, 23%)的产率得到6-chloro-2-(trifluoromethyl)-1,2-dihydro[1,8]naphthyridine-3-carboxylic acid
  参考文献：
  名称：

  Substituted benzopyran derivatives for the treatment of inflammation

  摘要：

  一类苯并吡喃衍生物被描述为用于治疗环氧合酶-2介导的疾病。特别感兴趣的化合物由公式I'定义，其中X，A1，A2，A3，A4，R，R"，R1和R2如规范中所述。

  公开号：

  US20050049252A1

文献信息

• Combination therapy for the treatment of cancer
  申请人：Pharmacia Corporation

  公开号：US20030216410A1

  公开（公告）日：2003-11-20

  The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.

  本发明涉及使用蛋白酪氨酸激酶抑制剂与环氧合酶抑制剂，特别是环氧合酶-2选择性抑制剂，联合治疗或预防肿瘤性疾病的方法。
• Therapeutic combinations for cardiovascular and inflammatory indications
  申请人：Pharmacia Corporation

  公开号：US20030199482A1

  公开（公告）日：2003-10-23

  The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises an ASBT inhibitor combined with COX-2 inhibitor. A further therapeutic combination comprises an ASBT inhibitor, a COX-2 inhibitor and an HMG Co-A reductase inhibitor. Another therapeutic combination comprises a chromene COX-2 inhibitor and an HMG Co-A reductase inhibitor.

  本发明提供了治疗组合物和方法，用于治疗或预防需要此类治疗或预防的受试者身上的高胆固醇血症相关或炎症相关疾病。一种治疗组合物包括ASBT抑制剂与COX-2抑制剂的组合。另一种治疗组合物包括ASBT抑制剂、COX-2抑制剂和HMG Co-A还原酶抑制剂。另一种治疗组合物包括一种香豆素类COX-2抑制剂和一种HMG Co-A还原酶抑制剂。
• Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
  申请人：Olson Maria Lisa

  公开号：US20050107350A1

  公开（公告）日：2005-05-19

  The present invention describes a novel method for preventing or treating bone disorders and bone disorder-related complications in a subject involving a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a bone disorder treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a bone disorder treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.

  本发明描述了一种新的方法，用于预防或治疗受体中的骨骼疾病和与骨骼疾病相关的并发症，包括单独使用Cox-2抑制剂或与骨骼疾病治疗剂的联合治疗。还描述了含有Cox-2抑制剂和骨骼疾病治疗剂的治疗组合物。还描述了用于实施本方法的药物组合物和工具包。
• Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
  申请人：Wax B. Martin

  公开号：US20050119262A1

  公开（公告）日：2005-06-02

  The present invention provides methods and compositions for the prevention and/or treatment of an optic neuropathy, comprising a Cox-2 inhibitor and an intraocular pressure reducing agent.

  本发明提供了一种预防和/或治疗视神经病变的方法和组合物，包括Cox-2抑制剂和降低眼内压的药物。
• Substituted benzopyran analogs for the treatment of inflammation
  申请人：G.D. Searle & Co.

  公开号：US20020010206A1

  公开（公告）日：2002-01-24

  A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I′ 1 wherein X, A 1 , A 2 , A 3 , A 4 , R, R″, R 1 and R 2 are as described in the specification.

  本发明涉及一类苯并吡喃、苯并噻吩、二氢喹啉、二氢萘及其类似物，用于治疗环氧化酶-2介导的疾病。特别感兴趣的化合物由式I'1定义，其中X、A1、A2、A3、A4、R、R″、R1和R2如规范所述。